Andreas Spiro
Long-term horizon, biotech, gold & precious metals, long/short equity

A New Trial Combining Fabrus And Senseco Technologies May Be Close At Hand

The Fabrus-Senesco (SNTI) merger has been creating a lot of hype, primarily because of Dr. Phillip Frost's position as Chariman of Fabrus, along with chairing Teva Pharmaceuticals (NASDAQ:TEVA), Opko (NYSEMKT:OPK) and Frost Gamma Investments Trust. He is a bit of a busy man. Frost has a long record of achievements, but the involvement of even a particularly green thumb should not be the sole criterion for making investment decisions, nor does it need to be in the case of Senesco.

Fabrus and Frost together bring two critical additions to Senesco. The first is, of course, money, which Senseco has been chronically short on. In one fell swoop, Senesco has gone from a peewee biotech with less...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details